US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MBX Biosciences

5.79

-0.2100-3.50%

Pre-market: 5.800.0100+0.17%05:08 EDT

Volume:322.16K

Turnover:1.88M

Market Cap:193.53M

PE:-1.00

High:6.50

Open:6.43

Low:5.63

Close:6.00

Loading ...

Overview Company News Filings

Stifel Nicolaus Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)

Microbix Biosystems to Release Q1 Fiscal 2025 Results and Host Webinar

MBX Biosciences Director Makes Bold Stock Move

Microbix Strengthens Financial Position with C$ 2.4 Million Equity Capital

Weight-loss drug developer Metsera raises $275 million in US IPO

MBX Biosciences to Participate in Upcoming February Investor Conferences

How Richard DiMarchi Revolutionized Diabetes Treatment

Microbix Expands Market Reach with Recombinant Antigen Production

MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action

BRIEF-MBX Biosciences Announces Positive Phase 1 Topline Results For MBX 1416 To Treat Post-Bariatric Hypoglycemia

MBX Biosciences announces phase 1 topline resuts for MBX 1416

Mbx Biosciences Announces Positive Phase 1 Topline Results for Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia

THOMSON REUTERS

Mbx Biosciences - Pending Alignment With FDA, Phase 2 Study of Mbx 1416 in Patients With Pbh Anticipated in Second Half of 2025

THOMSON REUTERS

Mbx Biosciences Inc - 1416 Generally Well-Tolerated With Favorable Safety Profile

THOMSON REUTERS

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

My Foodie Box Limited Announces Cessation of Securities Due to Unmet Conditions

Nasdaq Net Change Percentage Gainers & Losers

Nasdaq Net Change Percentage Gainers & Losers

Microbix Biosystems: Strong Q4 Performance and Promising Growth Prospects

Microbix Biosystems Reports Record Revenue Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MBX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":5.79,"timestamp":1744142400000,"preClose":6,"halted":0,"volume":322155,"hourTrading":{"tag":"盘前","latestPrice":5.8,"preClose":5.79,"latestTime":"05:08 EDT","volume":101,"amount":515.8000007,"timestamp":1744189706712},"delay":0,"floatShares":13617987,"shares":33424371,"eps":-5.818121,"marketStatus":"Pre-Market Trading","change":-0.21,"latestTime":"04-09 08:27:30 EDT","open":6.43,"high":6.498,"low":5.63,"amount":1877846.327325,"amplitude":0.144667,"askPrice":6.48,"askSize":29,"bidPrice":4.81,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.818121,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744205400000},"marketStatusCode":1,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":5.79,"preHourTrading":{"tag":"盘前","latestPrice":5.8,"preClose":5.79,"latestTime":"05:08 EDT","volume":101,"amount":515.8000007,"timestamp":1744189706712},"postHourTrading":{"tag":"盘后","latestPrice":5.79,"preClose":5.79,"latestTime":"19:13 EDT","volume":7521,"amount":43528.84,"timestamp":1744154022525},"volumeRatio":1.0571297312760335},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","floatShares":13617987,"roa":"-24.17%","roe":"-36.71%","lyrEps":-5.818121,"volumeRatio":1.0571297312760335,"shares":33424371,"dividePrice":0,"high":6.498,"amplitude":0.144667,"preClose":6,"low":5.63,"week52Low":4.8069,"pbRate":"0.75","week52High":27.5,"institutionHeld":0,"latestPrice":5.79,"committee":0.550388,"eps":-5.818121,"divideRate":0,"volume":322155,"delay":0,"ttmEps":-5.818121,"open":6.43,"prevYearClose":18.43,"prevWeekClose":6.04,"prevMonthClose":7.38,"prevQuarterClose":7.38,"fiveDayClose":6.86,"twentyDayClose":9.19,"sixtyDayClose":13.69},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MBX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510519958","title":"Stifel Nicolaus Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510519958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510519958?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:45","pubTimestamp":1739191535,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on MBX Biosciences, Inc. (MBX – Research Report) today. The company’s shares closed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-mbx-biosciences-inc-mbx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-mbx-biosciences-inc-mbx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","SF"],"gpt_icon":0},{"id":"2509786142","title":"Microbix Biosystems to Release Q1 Fiscal 2025 Results and Host Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2509786142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509786142?lang=en_us&edition=fundamental","pubTime":"2025-02-06 20:44","pubTimestamp":1738845844,"startTime":"0","endTime":"0","summary":"An announcement from Microbix Biosystms ( ($TSE:MBX) ) is now available. Microbix Biosystems Inc. announced the scheduled release of its Q1 fiscal ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-to-release-q1-fiscal-2025-results-and-host-webinar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-to-release-q1-fiscal-2025-results-and-host-webinar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4181","HST","BK4218","BK4585","BK4588","BK4007","MBX"],"gpt_icon":0},{"id":"2509330296","title":"MBX Biosciences Director Makes Bold Stock Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2509330296","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509330296?lang=en_us&edition=fundamental","pubTime":"2025-02-06 10:08","pubTimestamp":1738807703,"startTime":"0","endTime":"0","summary":"New insider activity at MBX Biosciences, Inc. ( ($MBX) ) has taken place on February 6, 2025. Director P. Kent Hawryluk has made a significant inve...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/mbx-biosciences-director-makes-bold-stock-move?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/mbx-biosciences-director-makes-bold-stock-move?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2508245564","title":"Microbix Strengthens Financial Position with C$ 2.4 Million Equity Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2508245564","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508245564?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:47","pubTimestamp":1738673278,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) just unveiled an update. Microbix Biosystems Inc. has secured C$ 2.4 million in new equity capital through the ex...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-strengthens-financial-position-with-c-2-4-million-equity-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-strengthens-financial-position-with-c-2-4-million-equity-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","MBX","BK4007","EQR","BK4585","BK4215"],"gpt_icon":0},{"id":"2507607306","title":"Weight-loss drug developer Metsera raises $275 million in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507607306","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507607306?lang=en_us&edition=fundamental","pubTime":"2025-01-31 08:01","pubTimestamp":1738281708,"startTime":"0","endTime":"0","summary":"Weight-loss drug developer Metsera raises $275 million in US IPOJan 30 (Reuters) - Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL3N3OQ2E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007","MBX"],"gpt_icon":0},{"id":"2505090744","title":"MBX Biosciences to Participate in Upcoming February Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2505090744","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505090744?lang=en_us&edition=fundamental","pubTime":"2025-01-23 21:00","pubTimestamp":1737637200,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., Jan.  23, 2025  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/23/3014215/0/en/MBX-Biosciences-to-Participate-in-Upcoming-February-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4092","MBX","BK4007","PBH","HP"],"gpt_icon":0},{"id":"2502048155","title":"How Richard DiMarchi Revolutionized Diabetes Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2502048155","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502048155?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:00","pubTimestamp":1736424023,"startTime":"0","endTime":"0","summary":"Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2025/01/LSmain011325diMarchi-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/01/LSmain011325diMarchi-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/management/leaders-and-success/richard-dimarchi-revolutionized-diabetes-treatment/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["MBX.AU","LU2264538146.SGD","SG9999014914.USD","LU1983299246.USD","SG9999018857.SGD","LU2491050071.SGD","SG9999014880.SGD","SGXZ99366536.SGD","IE00B1BXHZ80.USD","LU1035775433.USD","LU0471298694.HKD","LU0471298777.SGD","LU0106261372.USD","LU0203201768.USD","BK4534","LU2468319806.SGD","SG9999015945.SGD","NOV","LU1804176565.USD","LU0094547139.USD","SG9999018865.SGD","LU0820561818.USD","LU0456855351.SGD","LU0079474960.USD","BK7503","LU1093756168.USD","LU1878469433.USD","LU1989771016.USD","IE00BK4W5L77.USD","NOV.AU","LU2602419157.SGD","MBX","LU0882574055.USD","LU2237443382.USD","LU0354030438.USD","LU0096364046.USD","LU0820561909.HKD","LU2106854487.HKD","LU1023059063.AUD","LU2491050154.USD","LU0114720955.EUR","LU0256863811.USD","SG9999001176.SGD","SG9999015978.USD","LLY","IE00B4R5TH58.HKD","LU1868837136.USD","SG9999001176.USD","LU0061475181.USD","LU0640476718.USD"],"gpt_icon":1},{"id":"2501721823","title":"Microbix Expands Market Reach with Recombinant Antigen Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2501721823","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501721823?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:43","pubTimestamp":1736340239,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) has shared an update. Microbix Biosystems is expanding its capabilities to produce recombinant antigens using syn...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-expands-market-reach-with-recombinant-antigen-production?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-expands-market-reach-with-recombinant-antigen-production?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2501478730","title":"MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2501478730","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501478730?lang=en_us&edition=fundamental","pubTime":"2025-01-08 00:47","pubTimestamp":1736268424,"startTime":"0","endTime":"0","summary":"On Tuesday, MBX Biosciences Inc. revealed results from its Phase 1 single ascending dose and multiple ascending dose trial of MBX 1416 in healthy adult volunteers.MBX 1416 is the company’s investigational long-acting glucagon-like peptide 1  receptor antagonist, being developed for Post-Bariatric Hypoglycemia .PBH is a common and potentially serious complication that can occur after certain types of weight loss surgery.In the multiple ascending dose cohort, MBX 1416 median half-life was approximately 90 hours, supporting once-weekly administration, and at steady state the median Tmaxwas between 36 and 48 hours.In the multiple ascending dose cohort, MBX 1416 increased GLP-1 within 60 minutes of a mixed meal tolerance test, suggesting a pharmacodynamic  effect in healthy volunteers that may translate into a therapeutic benefit in PBH patients.Consistent with the known GLP-1 antagonism effect on gastric motility, a slight acceleration of gastric emptying was observed with MBX 1416 based o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mbx-biosciences-investigational-drug-weight-164704610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD","MBX","BK4023","PBH","LU1169589451.USD","LU1169590202.USD","BK4007"],"gpt_icon":0},{"id":"2501208860","title":"BRIEF-MBX Biosciences Announces Positive Phase 1 Topline Results For MBX 1416 To Treat Post-Bariatric Hypoglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2501208860","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501208860?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:17","pubTimestamp":1736252258,"startTime":"0","endTime":"0","summary":"Jan 7  - MBX Biosciences Inc   :   * MBX BIOSCIENCES ANNOUNCES POSITIVE PHASE 1 TOPLINE RESULTS FOR MBX 1416 FOR THE TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA   * MBX BIOSCIENCES INC - 1416 GENERALLY WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE   * MBX BIOSCIENCES - PENDING ALIGNMENT WITH FDA, PHASE 2 STUDY OF MBX 1416 IN PATIENTS WITH PBH ANTICIPATED IN SECOND HALF OF 2025Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4212","POST","MBX","BK4007"],"gpt_icon":0},{"id":"2501538208","title":"MBX Biosciences announces phase 1 topline resuts for MBX 1416","url":"https://stock-news.laohu8.com/highlight/detail?id=2501538208","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501538208?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:16","pubTimestamp":1736252171,"startTime":"0","endTime":"0","summary":"MBX Biosciences (MBX) announced positive results from its Phase 1 single ascending dose, SAD, and multiple ascending dose, MAD, clinical trial of M...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-announces-phase-1-topline-resuts-for-mbx-1416?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-announces-phase-1-topline-resuts-for-mbx-1416?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2501705532","title":"Mbx Biosciences Announces Positive Phase 1 Topline Results for Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2501705532","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501705532?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:00","pubTimestamp":1736251202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA2RL29M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2501270653","title":"Mbx Biosciences - Pending Alignment With FDA, Phase 2 Study of Mbx 1416 in Patients With Pbh Anticipated in Second Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501270653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501270653?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:00","pubTimestamp":1736251202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA2RL29M:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2501270569","title":"Mbx Biosciences Inc - 1416 Generally Well-Tolerated With Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2501270569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501270569?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:00","pubTimestamp":1736251202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA2RL29M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2501158270","title":"MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2501158270","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501158270?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:00","pubTimestamp":1736251200,"startTime":"0","endTime":"0","summary":"Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generall","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005223/0/en/MBX-Biosciences-Announces-Positive-Phase-1-Topline-Results-for-MBX-1416-for-the-Treatment-of-Post-bariatric-Hypoglycemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4092","BK4023","HP","LU1169590202.USD","DDI","PBH","BK4007","PD","LU1169589451.USD","MBX","BK4085","BK4212","POST"],"gpt_icon":0},{"id":"2501724349","title":"My Foodie Box Limited Announces Cessation of Securities Due to Unmet Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2501724349","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501724349?lang=en_us&edition=fundamental","pubTime":"2025-01-07 12:07","pubTimestamp":1736222879,"startTime":"0","endTime":"0","summary":"My Foodie Box Limited ( ($AU:MBX) ) has shared an update. My Foodie Box Limited announced the cessation of certain securities due to the lapse of c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/my-foodie-box-limited-announces-cessation-of-securities-due-to-unmet-conditions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/my-foodie-box-limited-announces-cessation-of-securities-due-to-unmet-conditions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BOX","BK4023","LU0106261612.USD","MBX","BK4007","LU0240878834.USD","LU0240877869.USD","LU0012050646.USD"],"gpt_icon":0},{"id":"2501963222","title":"Nasdaq Net Change Percentage Gainers & Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2501963222","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501963222?lang=en_us&edition=fundamental","pubTime":"2025-01-07 06:43","pubTimestamp":1736203380,"startTime":"0","endTime":"0","summary":"Copyright (c) 2025 Dow Jones & Company, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GB00BDT5M118.USD","BK4554","LU0719512351.SGD","IE00B7SZLL34.SGD","BK4533","NVIW.SI","TQQQ","LU1267930813.SGD","LU0056508442.USD","IE00B19Z3B42.SGD","BK4007","LU2211815571.USD","LU2048586759.USD","QLD","BK4553","LU0157215616.USD","NDAQ","QID","IE00BKPKM429.USD","LU2286300806.USD","LU1852331112.SGD","SQQQ","LU1366333091.USD","IE00B64PRP62.GBP","BK4532","LU0642271901.SGD","BK4575","BK4566","USAW.SI","BK4141","USJW.SI","PSQ","LU0127658192.USD","LU0792757196.USD","TSYW.SI","LU0889566641.SGD","LU1316542783.SGD","BK4527","IE00B3QW5Z07.USD","NQmain","IE00BGHQF748.EUR","MBX",".IXIC","LU2095319765.USD","MNQmain","BK4112","IE0002270589.USD","LU0082616367.USD"],"gpt_icon":1},{"id":"2495504527","title":"Nasdaq Net Change Percentage Gainers & Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2495504527","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495504527?lang=en_us&edition=fundamental","pubTime":"2024-12-31 06:43","pubTimestamp":1735598580,"startTime":"0","endTime":"0","summary":"Copyright (c) 2024 Dow Jones & Company, Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","PSQ","IE00B3QW5Z07.USD","BK4585","USAW.SI","QID","BK4112","LU2210149790.SGD","TQQQ","NDAQ","TSYW.SI","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","BK4007","NVIW.SI","BK4588","SQQQ","MNQmain","MBX","IE00B64PRP62.GBP",".IXIC","QLD","NQmain","USJW.SI"],"gpt_icon":1},{"id":"2493249685","title":"Microbix Biosystems: Strong Q4 Performance and Promising Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2493249685","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493249685?lang=en_us&edition=fundamental","pubTime":"2024-12-22 21:05","pubTimestamp":1734872711,"startTime":"0","endTime":"0","summary":"Bloom Burton analyst David Martin PhD maintained a Buy rating on Microbix Biosystms (MBX – Research Report) on December 20 and set a price target o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/microbix-biosystems-strong-q4-performance-and-promising-growth-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/microbix-biosystems-strong-q4-performance-and-promising-growth-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2492122238","title":"Microbix Biosystems Reports Record Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2492122238","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492122238?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:44","pubTimestamp":1734612284,"startTime":"0","endTime":"0","summary":"Microbix Biosystms (TSE:MBX) has released an update. Microbix Biosystems Inc. has achieved record revenues of $25.4 million for fiscal year 2024, d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-reports-record-revenue-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-reports-record-revenue-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":56,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-17","symbol":"MBX","fiscalQuarterEnding":"2024/12","expectedEps":-0.59,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"pre","actualEps":-0.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MBX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.75,"buy":0.25,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.75,"analysts":4,"updateTime":1728446400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MBX","date":"2025-04-08","current":-3.238691,"percent":1,"low":-18.37518,"twenty":-15.687509,"median":-10.949581,"eighty":-6.00289,"high":-3.238691,"avg":-10.435234,"sd":4.506216,"marketCap":200546226},"quantilePoints":[{"date":"2024-09-13","current":-10.797864,"twenty":-10.55484,"median":-10.190304,"eighty":-9.825767,"marketCap":509659168},{"date":"2024-09-20","current":-15.015591,"twenty":-15.168364,"median":-14.852916,"eighty":-11.560463,"marketCap":708735908},{"date":"2024-09-27","current":-17.32133,"twenty":-16.200444,"median":-15.47886,"eighty":-14.65927,"marketCap":817566764},{"date":"2024-10-04","current":-17.328403,"twenty":-17.001639,"median":-15.960592,"eighty":-14.885451,"marketCap":817900601},{"date":"2024-10-11","current":-16.663558,"twenty":-17.001639,"median":-16.288699,"eighty":-15.053784,"marketCap":786519924},{"date":"2024-10-18","current":-16.380645,"twenty":-17.034173,"median":-16.380645,"eighty":-15.256067,"marketCap":773166445},{"date":"2024-10-25","current":-16.366499,"twenty":-17.022857,"median":-16.518565,"eighty":-15.513518,"marketCap":772498771},{"date":"2024-10-31","current":-15.744091,"twenty":-17.017199,"median":-16.373572,"eighty":-15.206557,"marketCap":743121117},{"date":"2024-11-08","current":-14.04827,"twenty":-16.953543,"median":-16.31699,"eighty":-15.206557,"marketCap":775169467},{"date":"2024-11-15","current":-11.803503,"twenty":-16.939398,"median":-16.175534,"eighty":-14.610859,"marketCap":651305476},{"date":"2024-11-22","current":-9.99876,"twenty":-16.932325,"median":-15.949203,"eighty":-13.860717,"marketCap":551721571},{"date":"2024-11-29","current":-12.318278,"twenty":-16.904034,"median":-15.751164,"eighty":-12.256505,"marketCap":679710282},{"date":"2024-12-06","current":-11.682379,"twenty":-16.817745,"median":-15.461179,"eighty":-11.791391,"marketCap":644621993},{"date":"2024-12-13","current":-12.415177,"twenty":-16.690435,"median":-15.206557,"eighty":-11.939161,"marketCap":685057069},{"date":"2024-12-20","current":-12.275885,"twenty":-16.663558,"median":-14.934254,"eighty":-11.791391,"marketCap":677371062},{"date":"2024-12-27","current":-13.256987,"twenty":-16.659314,"median":-14.421446,"eighty":-11.803503,"marketCap":731507280},{"date":"2025-01-03","current":-11.052536,"twenty":-16.546149,"median":-14.047442,"eighty":-11.706604,"marketCap":609867878},{"date":"2025-01-10","current":-8.787523,"twenty":-16.380645,"median":-13.843492,"eighty":-11.523707,"marketCap":484886735},{"date":"2025-01-17","current":-6.383218,"twenty":-16.377816,"median":-13.75965,"eighty":-11.170026,"marketCap":352219585},{"date":"2025-01-24","current":-7.103904,"twenty":-16.366499,"median":-13.256987,"eighty":-10.797864,"marketCap":391986313},{"date":"2025-01-31","current":-7.049398,"twenty":-16.359427,"median":-13.057133,"eighty":-9.859468,"marketCap":388978745},{"date":"2025-02-07","current":-7.424882,"twenty":-16.31699,"median":-12.415177,"eighty":-8.842029,"marketCap":409697544},{"date":"2025-02-14","current":-5.444509,"twenty":-16.309917,"median":-12.318278,"eighty":-7.473331,"marketCap":300422587},{"date":"2025-02-21","current":-7.164466,"twenty":-16.270309,"median":-12.215323,"eighty":-7.193536,"marketCap":395328054},{"date":"2025-02-28","current":-5.947173,"twenty":-16.124609,"median":-12.009413,"eighty":-6.809573,"marketCap":328159044},{"date":"2025-03-07","current":-6.213645,"twenty":-15.986606,"median":-11.803503,"eighty":-6.598818,"marketCap":342862708},{"date":"2025-03-14","current":-5.226487,"twenty":-15.951481,"median":-11.682379,"eighty":-6.524932,"marketCap":288392317},{"date":"2025-03-21","current":-4.302061,"twenty":-15.898279,"median":-11.549143,"eighty":-6.302065,"marketCap":266392236},{"date":"2025-03-28","current":-3.999783,"twenty":-15.778041,"median":-11.258446,"eighty":-6.213645,"marketCap":247674589},{"date":"2025-04-04","current":-3.43841,"twenty":-15.745506,"median":-11.107042,"eighty":-6.061029,"marketCap":212913243},{"date":"2025-04-08","current":-3.238691,"twenty":-15.687509,"median":-10.949581,"eighty":-6.00289,"marketCap":200546226}],"updateTime":1744201651002}}}